For biotech CFOs, the realm of rare diseases is often ripe for pivots
A blockbuster drug — like erectile dysfunction treatment Viagra or statin Lipitor — can rev up sales and send a company's shares soaring. Medications for rare diseases, however, offer limited patient pools for clinical trials and market growth. And, many startup biotech companies tie their fortunes to a limited pipeline of potential treatments and live or die by the outcome of the FDA approval process.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063